Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.7.0.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Operating Costs and Expenses:        
General and administrative $ 1,644 $ 2,147 $ 3,734 $ 4,573
Research and development 4,831 7,164 10,891 15,319
Total Operating Costs and Expenses 6,475 9,311 14,625 19,892
Loss from Operations (6,475) (9,311) (14,625) (19,892)
Other Income:        
Change in fair value of warrant liability 2,159 3,513 7,249 3,015
Interest income 1 34 3 35
Total Other Income 2,160 3,547 7,252 3,050
Net Loss (4,315) (5,764) (7,373) (16,842)
Net Loss Attributable to Non-controlling Interest (60) (82) (272) (315)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries $ (4,255) $ (5,682) $ (7,101) $ (16,527)
Net Loss Per Share - Basic and Dilutive $ (0.03) $ (0.06) $ (0.06) $ (0.18)
Net Loss Per Share - Dilutive $ (0.03) $ (0.10) $ (0.06) $ (0.21)
Weighted average number of shares outstanding during the period - Basic 123,005,220 91,015,733 120,241,593 90,921,243
Weighted average number of shares outstanding during the period - Dilutive 123,005,220 93,930,540 120,241,593 92,651,215